Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Gross Profit | -3.3M | 11.7% |
| Cost of Revenue | 3.3M | 11.7% |
| Operating expense | 6.5M | 9.1% |
| Net Income | -4.8M | 7.7% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 43M | 7.1% |
| Total Liabilities | 25M | 3% |
| Total Equity | 15M | 8.9% |
| Shares Outstanding | 3.2M | 6% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | -6.4M | 4.6% |
| Cash from financing | 2.5M | 0% |
EPS
Financial Highlights for vTv Therapeutics in Q3 '24
Gross Profit stood at -3.3M, marking a 11.7% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 3.3M, a -11.7% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 6.5M, showing a -9.1% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -4.8M, showing a 7.7% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's performance remained stable this quarter with no significant positive or negative changes in the key financial metrics.
